Clinical trials: APOL1-mediated Kidney Disease, open to volunteers
Proteinuric Kidney Disease
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
- Trial name
- NCT06830629
- Testing
- MZE829
- Where
- 79 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Maze Therapeutics
APOL1-mediated Kidney Disease
APOL1 Genotyping CTA Clinical Performance Study
Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment.
- Trial name
- NCT06839833
- Testing
- APOL1 Genotyping
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Almac Diagnostic Services LLC